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duration. Median age was 61 years (range 30-83). Fourteen 
patients had confirmed SS. Eighteen patients were female (12 
with SS) and 8 were male (2 with SS). Stage of disease 
includes: stage 1 (17 patients) stage 2 (7), stage 3 (1) and 
stage 4 (1). Patients with SS were treated with 4Gy and 
patients without SS were treated with 25.2Gy, unless they 
had advanced stage. Sites treated include: parotid (13 
patients), orbit or conjunctiva (6), thyroid (1), tongue (1), 
palate (4) & spine (1) Indications for treatment included 
pain, recurrent inflammation or unsightly mass. 17 patients 
received 4 Gy in 2 fractions (13 with SS) and 9 patients 
received 25.2 Gy in 14 fractions (1 with SS). 
 
Results: The objective response rate (ORR= CR + PR, assessed 
6 weeks after RT) was 100%. Twenty-two patients (84.6%) 
remain progression-free at the time of writing with median 
FU of 89 months (range 22 - 144). Two males (1 with SS) and 
one female had disease progression in the treated area at 3, 
36 and 19 months respectively. All 3 relapses occurred in 4Gy 
dose group. Two patients were subsequently retreated with 
further 4Gy/2# and 20Gy/5# and achieved further 
progression-free survival of 36 and 60 months respectively. 
One female patient (4Gy/2#) underwent transformation to 
diffuse large B-cell lymphoma at 36 months. The distribution 
of relapses is summarised in table 1. Radiotherapy was well 
tolerated in all patients, with the most common long-term 
side effect being dry mouth in 3 patients (11.5%), cataract in 
1 patient and watery eye in 1 patient. All three patients who 
reported dry mouth were known to have SS. 
 
Conclusion: Radiotherapy is a very effective treatment for 
head and neck MALT lymphoma resulting in high response 
rate, durable local control and minimal toxicity. There were 
no relapses after 25.2Gy and only few relapses (3/17) after 
4Gy, 2 of which had durable remission following re-
treatment. 
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Purpose or Objective: The purpose of this study was to 
estimate risk and incidence of second malignant neoplasms 
(SMN) among long-term survivors of early stage extranodal 
nasal-type natural killer/T-cell lymphoma (NKTCL). 
 
Material and Methods: Between January 1983 and December 
2007, 174 patients with stage IE and IIE NKTCL survived 3 or 
more years after treatment. Of them, 50 patients were 
treated with radiotherapy alone, 120 patients with combined 
modality therapy, and 4 patients with chemotherapy alone. 
The China 2010 population census data and Segi’s world 
population data were used for calculating the age-
standardized cancer incidence rates. 
 
Results: Median follow-up time was 8.3 years (range, 3.1 - 
35.6 years) for all patients. Nine (5.2%) SMNs were recorded. 
The median time to SMN was 12.6 years (range, 0.9 - 18.5 
years) from diagnosis of NKTCL. Seven patients had solid 
tumors, and 2 had other type of malignant lymphomas. The 
cumulative incidence rates at 5-year, 10-year and 15-year 
were 1.2%, 2.4%, and 13.7% (Figure), respectively. The crude 
incidence was 531.6/105 person-years, the age-standardized 
rates by Chinese standard population (ASR China) and by 
world standard population (ASR world) were 294.5/105 and 
243.7/105, and the cumulative incidence rate (0-74 age years 
old) was 22.4%. All of them were higher than the cancer 
incidence rates for general population in China in 2010. 
 
 
Conclusion: A frequency of SMN in patients with NKTCL is 
higher than expected in the general population. The patients 
have more risk for SMN during 10 to 15 years after diagnosis 
of NKTCL. Patients with long-term survivor are at higher risk 
of SMN and should be carefully follow-up. 
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Purpose or Objective: Low dose radiotherapy (LDRT) 
provides effective palliation and local disease control in 
patients with low grade non Hodgkin lymphoma (LGNHL). Its 
role in high grade NHL (HGNHL) remains unclear.  
The purpose of this study was to evaluate the efficacy of 
LDRT in relapsed/refractory (RR) HGNHL.  
 
Material and Methods: We performed a retrospective review 
of all patients undergoing LDRT for RR HGNHL at our 
institution. LDRT was defined as a total dose of 8Gy or less in 
1 or more fractions.  
Sex, age, histological type, time from diagnosis to LDRT and 
number of prior systemic therapies were recorded, along 
with radiotherapy dose and site treated.  
Outcomes included overall response rate (ORR), in field 
recurrence, time to progression (TTP) and overall survival 
from completion of RT. Toxicity was also recorded. Analysis 
was performed by site and by patient as a number of patients 
had more than 1 site treated at different times.  
 
Results: Between August 2004 and September 2015 15 
patients received LDRT for HGNHL. 5 patients had >1 site 
treated, with LDRT being given to 37 sites in total. Most 
patients (12/15) had a diagnosis of diffuse large B cell 
lymphoma, which accounted for 32/37 (86.5%) of all sites. 
Patient and treatment characteristics are shown in table 1.  
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Overall response rate (ORR) for all sites was 89.2% (33/37 
sites). 17 sites (45.9%) achieved a complete response (CR) 
and 16 sites (43.2%) a partial response. 4 sites (10.8%) did not 
respond to LDRT. Considering ORR by patient, 11/15 patients 
(73.3%) had a response to LDRT at all sites, 3/15 (20%) did 
not respond and 1 patient responded at 2 sites but not the 
3rd. 
Skin was the most commonly treated site (19/37, 51.4%) and 
skin sites had the highest ORR at 100%, with 73.7% (14/19) 
CR. This was statistically significant when compared to all 
other sites (p=0.046). ORR for nodal sites was 83.3% (5/6) and 
extra-nodal sites was 85.7% (6/7). Bone sites had the lowest 
ORR at 60% (3/5 cases) with no CR.  
16 sites received a total dose of 4Gy in 1 or 2 fractions. 21 
sites received either 6 or 8Gy in total. ORR in both groups 
was similar (87.5% versus 90.5%, p =1). Toxicity from LDRT 
was minimal, with no toxicity recorded above grade 2.  
Of the 33 initially responding sites there have been 4 infield 
recurrences (12.1%). Median TTP was 4.8 months (3.1-11.8). 
2 sites were retreated with further symptomatic benefit. 
Median duration of response was 3.6 months (0.5-126.7). 6 
sites (2 patients) had responses lasting >30 months. The 
majority of patients died without documented local 
recurrence, with median overall survival from LDRT of 2.4 
months (0.03-126.7). 
 
Conclusion: LDRT is an effective palliative treatment for 
patients with RR HGNHL and anticipated short survival, 
achieving high response rates and excellent local control, 
with minimal toxicity and inconvenience. A small subgroup of 
patients with slowly relapsing disease derived durable 
remissions with LDRT. 
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Purpose or Objective: Hodgkin lymphoma (HL) has become a 
highly curable lymphoid malignancy. The improved prognosis 
of HL has been accompanied by increasing incidence of 
adverse late effects. Mediastinal radiotherapy (RT) and 
cardiotoxic chemotherapy (CT) with anthracyclines are 
routinely used to treat HL, but they could be associated with 
a variety of cardiovascular complications in long-term HL 
survivors. The aim of this study is to evaluate the late 
cardiovascular toxicity of a series of 202 patients treated 
from 1995 to 2012. 
 
Material and Methods: 420 patients (pts) were treated for HL 
with RT +/- CT at our institution from 1995 to 2012. All the 
alive patients were contacted and invited to participate to 
the study. A detailed medical history of the 202 pts who 
accepted and subscribed informed consent was obtained, 
collecting events occurred after treatment; they had medical 
examination, ECG, Echocardiogram TT and blood tests. 
Treatment features were extracted from medical records. 
The entire group was divided in two groups: 157 pts received 
mediastinal RT (cases) and 45 pts did not (controls). The 
cardiac events were categorized using CTCAE ver. 4.0. A 
preliminary descriptive statistic using SPSS® software (χ2 
test) has been performed and here presented. The contouring 
of the different cardiac structures for dosimetric evaluation 
is ongoing. 
 
Results: The patients and therapeutic characteristics of the 
patients are summarized in Table 1. After a median follow-up 
of 8 years (range 2-20 years) 144 pts (71,3%) manifested 
cardiac alterations: 1,0% arrhythmia, 2,5% ischemia, 1,5% 
heart failure and 66,3% valvular fibrosis without statistical 
differences between cases and controls. Most patients 
(75,4%) had asymptomatic grade I-II valvular fibrosis; only 
one had grade III valvular fibrosis. After treatment, with a 
median follow up time of 11,2 years, (range 4,1-17,8 years), 
acute myocardial infarction occurred in 5 pts, all in the group 
of cases. 
 
 
 
Conclusion: The study does not show a direct association 
between late cardiac toxicity and mediastinal RT. Multi-
parametric statistical analysis to evaluate a possible 
